MET Labs just completed testing for its first product to be sent to the Medical Device RFID Susceptibility Program.
In coordination, MET Labs and the U.S. Food and Drug Administration (FDA) have designed the test product to find out any potential harm that radio frequency identification emissions can cause to medical devices.
At MET’s Santa Clara, California laboratory in Silicon Valley, the patient worn battery operated vital sign monitoring device was tested. It passed six of seven tests. The testing led to the discovery that when the device was subject to 860-960 MHz frequency at RFID at 54V/m, the device was at fault.
The testing was done with RF parameters which enabled the emission of minimum and maximum occupied bandwidth. The testing results ranged from 134.2 kHz at 160 A/m and 2.45 GHz at 54 V/m.
Ted Osinski, MET Labs RFID Program Manager, stated that the testing is done to prepare for the worst case scenario so that the healthcare arena in which such devices are used can be completely free of any risk as a result of RFID technology and its emissions.
He looks forward to mitigating any factors that could potentially create any future issues.